6-K ·Filed May 12, 2026

RDY

DR REDDYS LABORATORIES LTD
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago SEC0001575872-26-000293
Notable filing: 6-K
Actionable Insight • Neutral

This filing contains only routine governance changes with no financial data or strategic updates. No trading action warranted. Monitor upcoming quarterly results for fundamental performance signals.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d ⚠ clustered
RDY ▼ -2.81% at T+60d
NEUTRAL call ✗ call lost -2.81% · α vs SPY -7.19% · entry $12.46 → $12.11
Entry anchored
May 12, 10:02 AM ET
via exchange tick
T+1d
+4.25%
call +4.25% · α +3.68%
$12.99
settled 5mo ago
T+5d
+9.15%
call +9.15% · α +9.07%
$13.60
settled 5mo ago
T+20d
+6.74%
call +6.74% · α +8.47%
$13.30
settled 4mo ago
T+60d
-2.81%
call -2.81% · α -7.19%
$12.11
settled 8w ago

Price Chart

Loading chart...

Executive Summary

Dr. Reddy's filed a routine 6-K reporting board meeting outcomes: re-appointment of an independent director, appointment of a new independent director, appointment of Deloitte as statutory auditor, re-appointment of cost auditor, and elevation of a senior management personnel. No financial results, guidance, or material business developments were disclosed.

Key Facts

  • Board re-appointed Dr. K P Krishnan as Independent Director for a second term from Jan 7, 2027 to Jan 6, 2032
  • Board appointed Mr. Srikanth Velamakanni as Independent Director for a term from Jul 1, 2026 to Jun 30, 2031
  • Board appointed Deloitte Haskins & Sells LLP as statutory auditors for five years from the 42nd AGM
  • Board re-appointed M/s Sagar & Associates as cost auditors for FY 2026-27
  • Mr. Sandeep Khandelwal elevated to Senior Management Personnel and Management Council member
  • No financial results, guidance, or material business updates were provided

Financial Impact

No financial figures disclosed in the filing

Risk Factors

  • No material risks identified from this routine filing

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
50% bullish (44 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001575872-26-000293
Document: 0001575872-26-000293-index.html0001575872-26-000293
Document: 0001575872-26-000293.txt0001575872-26-000293
51 reports for RDY
Performance horizon
67% Hit rate 6 of 9 directional calls best @ T+20▲ +23.28%Jun 26, 2026
Filters
Rows
Reports for RDY — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
6-K
NEUTRAL ★ 3/10
$11.91 $11.55▼ −3.02%▼ −2.56%$12.25 (+2.85%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 5/10
$11.71 $11.90▲ +1.62%▲ +0.77%$12.25 (+4.61%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 2/10
$11.71 $11.90▲ +1.62%▲ +0.77%$12.25 (+4.61%)
Aug 26, 2026
5w ago
6-K
NEUTRAL ★ 2/10
$12.22 $12.16▼ −0.49%▼ −1.15%$12.25 (+0.25%)
Aug 17, 2026
6w ago
6-K
MIXED ★ 5/10
$12.11 $12.15▲ +0.33%▲ +1.01%$12.25 (+1.16%)
Aug 13, 2026
7w ago
6-K
NEUTRAL ★ 3/10
$12.42 $12.27▼ −1.21%▼ −1.01%$12.25 (−1.37%)
Aug 10, 2026
7w ago
6-K
NEUTRAL ★ 2/10
$12.15 $12.45▲ +2.47%▲ +2.79%$12.25 (+0.82%)
Aug 3, 2026
8w ago
6-K
BULLISH ★ 6/10
$12.07 $12.10▲ +0.25%▼ −1.55%$12.25 (+1.49%)
Jul 29, 2026
9w ago
6-K
NEUTRAL ★ 4/10
$11.76 $11.83▲ +0.60%▼ −1.08%$12.25 (+4.17%)
Jul 23, 2026
10w ago
6-K
NEUTRAL ★ 2/10
$11.80 $11.79▼ −0.08%▼ −0.19%$12.25 (+3.81%)
Showing 10 of 51

US Market Status

Market Closed — Opens Mon (65h 27m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access